Associations - NF1 mutation

NF1 mutation NF1 mutation	CNS Tumor CNS Tumor	NF1 mutation NF1 mutation	CNS Tumor CNS Tumor	selumetinib Sensitive: C3 – Early Trials	selumetinib Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Glioma Glioma	NF1 mutation NF1 mutation	Glioma Glioma	trametinib Sensitive: C3 – Early Trials	trametinib Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Melanoma Melanoma	NF1 mutation NF1 mutation	Melanoma Melanoma	vemurafenib Resistant: C3 – Early Trials	vemurafenib Resistant: C3 – Early Trials
NF1 mutation NF1 mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	NF1 mutation NF1 mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials	atezolizumab + cobimetinib Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Colorectal Cancer CRC	NF1 mutation NF1 mutation	Colorectal Cancer CRC	AZD6738 Sensitive: C3 – Early Trials	AZD6738 Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Multiple Myeloma Multiple Myeloma	NF1 mutation NF1 mutation	Multiple Myeloma Multiple Myeloma	MEK inhibitor Sensitive: C3 – Early Trials	MEK inhibitor Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Solid Tumor Solid Tumor	NF1 mutation NF1 mutation	Solid Tumor Solid Tumor	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
NF1 mutation NF1 mutation	Melanoma Melanoma	NF1 mutation NF1 mutation	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
NF1 mutation NF1 mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	NF1 mutation NF1 mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies	vandetanib Sensitive: C4 – Case Studies
NF1 mutation NF1 mutation	Sarcoma Sarcoma	NF1 mutation NF1 mutation	Sarcoma Sarcoma	SAR442720 Sensitive: C4 – Case Studies	SAR442720 Sensitive: C4 – Case Studies
NF1 mutation NF1 mutation	Melanoma Melanoma	NF1 mutation NF1 mutation	Melanoma Melanoma	VTX-11e Resistant: D – Preclinical	VTX-11e Resistant: D – Preclinical
NF1 mutation NF1 mutation	Melanoma Melanoma	NF1 mutation NF1 mutation	Melanoma Melanoma	PD-0325901 Sensitive: D – Preclinical	PD-0325901 Sensitive: D – Preclinical
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical	DR6MP + JHU395 Sensitive: D – Preclinical
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	DR6MP Sensitive: D – Preclinical	DR6MP Sensitive: D – Preclinical
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical